Tri-Service Medical Center
Taipei, Taiwan
NCT Number: NCT03616275
This is a 2-year course of study. A randomized control trial will be conducted, in which 90 prediabetes individuals will be recruited and randomly assigned them into the wait-list control group or experimental group to test the effectiveness of 8 once-a-week, individual, 20-min sessions of HRV biofeedback on modulating vagal tone, glycemic control, psychological wellbeing, and inflammatory status in this population. Its longitudinal effects will be evaluated after 3- and 6-month follow-up.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Not applicable
Taipei, Taiwan
Background. Compared to healthy population, individuals with prediabetes have a higher risk to develop diabetes and other cardiovascular diseases. However, these downward progressions might positively associate with autonomic nervous dysfunction, especially low vagal tone, which can be detected prior to comorbidities confirmed. The significant correlations among low autonomic nervous, high psychological distress, inflammatory status, and poor glycemic regulation, which are regarded as the psychoneuroimmunological integration, have not been well studied in prediabetes individuals. Heart rate variability (HRV) biofeedback is an easy and noninvasive intervention, which has been confirmed to strengthen baroreflex stimulation, facilitate the modulation of vagal tone, and further promote the physiological and psychological wellbeing in various diseases but not in prediabetes.
Objective. To test the effectiveness of HRV biofeedback on the modulating vagal tone and further enhancing the psychoneuroimmunological integration related to glycemic control, anti-inflammatory reaction, and psychological wellbeing.
Research methods. In this 2-year RCT study, the investigators are planning to recruit 90 prediabetes individuals and randomly assigned them into wait-list control group or experimental group by using the random sequence of numbers generated from the Excel Bernoulli Function. Experimental group will receive 8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education. During the biofeedback training period, subjects will be encouraged to self- home practice of resonant frequency breathing for 20 mins, twice-a-day. Control group will receive 1 session of healthy lifestyle education. All subjects will be repeatedly assessed at time of enrollment, post-training (8 weeks after enrollment), 3-month, and 6-month follow-up. Repeated assessments will include physiological measurements of HRV, BDNF, GAS6, HbA1c, CRP, IL- 6, FPG, and salivary cortisol, and psychological measurements of perceived stress, anxiety, and depression.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
Time frame: baseline, 3-month, and 6-month visits
Heart rate variability (HRV) was used to represent the autonomic function, and measured with Mind Media B.V. (NeXus-10, Netherlands). Time and frequency domains of HRV was analyzed using Kubios HRV software (Biosignal Analysis and Medical Imaging Group, Finland).
Time frame: baseline, 3-month, and 6-month visits
The hospital anxiety and depression scale was a 14-item ordinal scale, used for participants to self-rate their psychological distress related to anxiety (7 items) and depression (7 items). Items are scored 0(no distress) to 3 (serious distress). Based on the findings from previous studies, scoring at or higher than the cut-off point of 8 out of 21, identified those with anxiety or depression.
Time frame: baseline, 3-month, and 6-month visits
Perceived stress was measured using the Chinese version of the Perceived Stress Scale (PSS), through which the participants self-reported about how they cope with, react to, and feel about various stressors. The PSS is a 5-point scale that ranges from 0 (never) to 4 (very often) with 14 items (seven negative and seven positive).
Time frame: baseline, 3-month, and 6-month visits
All blood will be drawn in the morning, between 8 and 10 a.m., and will immediately be separated by centrifugation at 2000 r/min for 10 minutes at 4 oC. CRP, BDNF, and GAS6 will be measured with a sandwich enzyme-linked immunoassay (ELISA) using a DuoSet ELISA Development kit (R&D Systems Catalog # DY1707). IL-6 will be measured by the BD™ CBA Human Soluble Protein Flex Set System with discrete fluorescence intensities to detect soluble analytes at very low concentrations. The HbA1c value will be measured by high-performance liquid chromatography, using the Primus CLC385 (Primus Corporation, Kansas City, MO). The FPG will be measured using a Reflotron reflectance photometric analyzer (Boehringer Mannheim, Germany).
Time frame: baseline, 3-month, and 6-month visits
Participant will be requested to collect the saliva before breakfast, approximately 30 minutes after awakening and before they brushed their teeth. The sample will be immediately frozen and transported to the laboratory for cortisol concentration measurement and analyzed using a commercial ELISA kit (Calbiochem, Darmstadt, Germany). All salivary variables are normalized by salivary flow rate.
National Defense Medical Center, Taiwan
Other
Improving the Glycemic Regulation and the Psychoneuroimmunological Function by Enhancing the Vagal Tone in Prediabetes Individuals
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07618663
Diabetes Mellitus, Endocrine System Diseases
Lahore, Shaikhupura, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial DetailsNCT07713394
Behavior, Body Weight
Erzurum, Turkey, Turkey (Türkiye)
View Trial DetailsNCT07710898
Diabete Mellitus, Diabetes Mellitus
Lahore, Pakistan
View Trial Details